Sanders Morris Harris LLC Purchases Shares of 10,000 Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM)

Sanders Morris Harris LLC acquired a new position in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNMFree Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $78,000.

Separately, Creative Financial Designs Inc. ADV grew its position in Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 3,175 shares in the last quarter. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, May 5th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Actinium Pharmaceuticals in a research report on Monday, June 17th. Stephens began coverage on Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They set an “overweight” rating and a $25.00 target price on the stock. Finally, Maxim Group increased their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Actinium Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $25.60.

Read Our Latest Stock Analysis on ATNM

Actinium Pharmaceuticals Price Performance

Shares of ATNM traded down $0.24 during mid-day trading on Friday, hitting $7.31. The stock had a trading volume of 418,917 shares, compared to its average volume of 163,921. The firm has a market cap of $217.69 million, a PE ratio of -4.27 and a beta of 0.12. Actinium Pharmaceuticals, Inc. has a 52 week low of $4.00 and a 52 week high of $10.24.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNMGet Free Report) last posted its earnings results on Friday, April 26th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.11. Sell-side analysts anticipate that Actinium Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Actinium Pharmaceuticals

(Free Report)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.

Further Reading

Want to see what other hedge funds are holding ATNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNMFree Report).

Institutional Ownership by Quarter for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.